AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.380
+0.020 (1.47%)
Apr 1, 2025, 4:00 PM EDT - Market closed

AN2 Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-51.32-64.73-40.96-21.54-13.6
Upgrade
Asset Writedown & Restructuring Costs
----0.65
Upgrade
Loss (Gain) From Sale of Investments
-3.28-2.86-0.690.05-
Upgrade
Stock-Based Compensation
8.348.414.390.970.04
Upgrade
Other Operating Activities
-0.050.08-6.32
Upgrade
Change in Accounts Payable
0.640.552.50.420.08
Upgrade
Change in Other Net Operating Assets
-3.645.281.22-0.391.14
Upgrade
Operating Cash Flow
-49.26-53.29-33.46-20.48-5.36
Upgrade
Investment in Securities
54.59-43.28-21.77-50.02-
Upgrade
Investing Cash Flow
54.59-43.28-21.77-50.02-
Upgrade
Issuance of Common Stock
0.3784.9970.370.010.06
Upgrade
Repurchase of Common Stock
---0.01--
Upgrade
Other Financing Activities
----1.21-
Upgrade
Financing Cash Flow
0.3784.9970.3678.543.84
Upgrade
Net Cash Flow
5.7-11.5715.128.03-1.53
Upgrade
Levered Free Cash Flow
-29-28.85-19.3-11.96-3.27
Upgrade
Unlevered Free Cash Flow
-29-28.85-19.3-11.96-3.27
Upgrade
Change in Net Working Capital
3.24-6.26-2.73-0.55-1.24
Upgrade
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q